GET A PIECE OF EVA MEDTEC
Automated Lymphatic Therapy (ALT) Technology
$104,832.79 Raised
REASONS TO INVEST
The Neuroglide™ by Eva Medtec makes it possible for anyone to experience the benefits of automated lymphatic therapy with one simple, at-home system. The company’s proprietary technology has received FDA-clearance for pain relief and increased circulation, which has numerous physical health benefits.
By developing non-invasive solutions that can be accessed without the need for a prescription, Eva Medtec is targeting the $4B Pain Management Devices market, which is expected to reach more than $8.5B by 2030 (8.5% CAGR). With additional therapy attachments currently in development, Eva Medtec also plans to address the $18.6B Stress Management Market as well as the $30B+ Sleep Health Market as the company looks to expand the Neuroglide’s FDA labeling.*
At the helm of Eva Medtec’s operations is a team of passionate founders with decades of combined medical and marketing experience seeking to continually evolve the company’s product pipeline with new innovations for the med-tech market. All products developed by Eva Medtec are based on extensive in-field expertise and are made in the U.S. by a full, in-house manufacturer.
*Market information provided by Precedence Research, Globe Newswire, and McKinsey & Company (source, source, source)
the pitch
Eva Medtec is the creator and manufacturer of Neuroglide™, an over-the-counter, FDA-cleared medical device engineered to automate and emulate manual lymphatic drainage (MLD) therapy. Lymphatic fluid carries toxins and other debri from cells of the body. When this fluid builds up in the lymphatic vessels, the body can have a number of negative reactions, including swelling and discomfort. MLD therapy seeks to accelerate lymph flow and decongest the body’s soft tissues of excess lymph, a practice with many associated health benefits – including pain management, improved rest, relaxation, and recovery.
Holistic Methodology Meets Modern Innovation
The Neuroglide™ is a back and neck device that emulates the precise pressure profiles and principles of manual lymphatic drainage (MLD) therapy in order to make this highly-specialized modality more available and accessible to all.
The technology was developed with the expertise of a certified MLD therapist, Eva Medtec's Founder & CTO, Irene Waldridge. Irene previously founded a publicly traded, market-leading lymphedema company, Tactile Medical (NASDAQ: TCMD), which at one point held a $1.2B market cap.* Irene’s experience practicing the techniques of MLD led her to witness its many health benefits firsthand. Because lymphatic therapy supports the body’s immune and autonomic nervous systems, MLD treatment has the potential to improve patient outcomes in cases of acute pain, injury, chronic pain, and other chronic conditions.
*Eva Medtec's leadership experience is not a guarantee of future performance or success.
The Problem & Our Solution
Bringing Together Technique and Technology to Provide Therapeutic At-Home Care
In recent years, more medical and therapeutic professionals have begun to recognize the body’s lymphatic system as having an important impact on overall health and wellness. Increased lymph circulation is linked to improved immune function, as well as reduction of swelling, congestion, and inflammation. However, because MLD therapy is an advanced modality available only through a handful of certified professional practitioners, most people aren’t able to access lymphatic therapy as often as needed for it to be truly effective.
(source)
Understanding this, Eva Medtec sought to develop a fully-automated device that can be used from the comfort of home, capable of producing benefits similar to receiving hands-on treatment. Utilizing an array of air channels that inflate and deflate in sequence, the Neuroglide™ is able to emulate the proper pressure, tempo, and mechanics needed to access the lymphatic system, promoting healthy flow of lymph throughout the entire body. This technology has been cleared by the FDA for pain relief and increased circulation, and is easy to use, anywhere, at any time.
The Market & Our Traction
Backed by Science and Built to Serve Multiple Market Verticals
In order to introduce the Neuroglide™ to the commercial market, Eva Medtec has obtained Class II FDA clearance for pain relief and increased circulation, as well as utility patent status for our proprietary technology. With these proof-positive elements in place, the company has been able to generate our first $100K in sales.
In pilot clinical patient trials, users of Neuroglide™ reported reduced back and neck pain, more restorative and consistent sleep, improved athletic recovery, and reduced pain from fibromyalgia.
As Eva Medtec works to expand awareness and accessibility to MLD therapy, the company is equally as excited about the planned, future therapy devices currently in development. These devices are designed for use with specific body regions such as the knee, lower legs, lumbar, and head, and work with the Neuroglide’s Controller Unit at launch. In addition to further developing the company’s product line, Eva Medtec also plans to expand Neuroglide’s FDA labeling into other benefit cases such as improved sleep, stress reduction, and athletic recovery.
Why Invest
Trusted Technology on Trend to Provide Positive Impact
As lymphatic therapies and MLD continue to generate a buzz in the medical sector as well as amongst A-list celebrities, such as Jennifer Aniston, the Kardashians, and Ariana Grande, Eva Medtec anticipates a growing trend of consumers looking to experience its many health benefits for themselves. Even so, because MLD remains a niche modality available only to a limited market, the company expects automated devices such as the Neuroglide™ have great potential to be widely embraced by at-home consumers.
With support from funding, Eva Medtec is poised for expansion and looks forward to offering an affordable, accessible solution that improves people’s daily lives. Be a part of Eva Medtec's mission by investing today!
Neuroglide™ is a Class II, over-the-counter FDA cleared medical device intended for the temporary relief of minor muscle aches and pains and for the temporary increase in circulation to the treated areas.
ABOUT
HEADQUARTERS
6300 W. Old Shakopee Road, Ste 140
Bloomington, MN 55438
WEBSITE
View Site
Eva Medtec is a medical technology enterprise that launched commercially in 2021 with its flagship product, the Neuroglide™, and has raised $3.7M to date.
TEAM
John Foster Dinusson
President & CEO
Irene Anne Waldridge
Founder/CTO
David Edward Rupp
VP of Marketing
Toni May Hastings
VP of Administration
Mark Melin, MD
Medical Director
Dan Sipple, DO
Medical Advisor
Doug Goldstein, DPT
Medical Advisor
TERMS
Eva Medtec
Overview
PRICE PER SHARE
$1.49
DEADLINE
Mar 21, 2023
VALUATION
$11.03M
FUNDING GOAL
$10k - $1.23M
Breakdown
MIN INVESTMENT
$299.49
MAX INVESTMENT
$1,234,999.91
MIN NUMBER OF SHARES OFFERED
6,711
MAX NUMBER OF SHARES OFFERED
828,859
OFFERING TYPE
Equity
ASSET TYPE
Common Stock
SHARES OFFERED
Common Stock
Maximum Number of Shares Offered subject to adjustment for bonus shares
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.
Voting Rights of Securities Sold in this Offering
Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
Investment Incentives and Bonuses*
Time-Based:
Friends & Family Bonus
Invest within the first 48 hours and receive 20% bonus shares.
Super Early Bird Bonus
Invest within the first week and receive 10% bonus shares.
Early Bird Bonus
Invest within the first two weeks and receive 5% bonus shares.
Amount-Based:
$700
Invest $700 and receive 2% bonus shares.
$1,500+ | Tier 1
Invest $1,500 and receive 4% bonus shares.
$5,000+ | Tier 2
Invest $5,000 and receive 7% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD)
$10,000+ | Tier 3
Invest $10,000 and receive 15% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD)
$25,000+ | Tier 4
Invest $25,000 and receive 20% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD)
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
Eva Medtec, Inc will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Class B Non-Voting Common Stock at $3.20/share, you will receive 10 additional shares of Non-Voting Common Stock, meaning you'll own 110 shares for $320. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Inter company debt or back payments.
ALL UPDATES
Stack Owner's Bonus & Rewards!
Members get an extra 10% shares in addition to rewards below!
REWARDS
JOIN THE DISCUSSION
0/2500
John Dinusson
Eva Medtec
•
7 months ago
Richard,
I greatly appreciate your interest in the Neuroglide system for the back and neck. No patient is a waste of time for our company as you are who we serve. We are cleared by the FDA for pain and circulation. I have an email into our Medical Director to get his feedback on your exact situation as it relates to the Neuroglide. Please feel free to give me a call on my cell at 952-217-6366 to discuss.
Best regards,
John
0
0
Richard Koch
7 months ago
I'm a chronic pain patient. Without either of us parsing conditions farther than neuropathy and a trashed spine, how could this product help me? I do, for reference, have a Medtronic Syncromed II implanted pushing fentanyl into my spine. Is this the next best thing for pain patients, or just for some pain patients (which I understand). My pain doc has never mentioned this type of therapy, so don’t understand the application and to which patients and for which conditions. I'm always looking for something to make my life a little less agonizing as well as for a good investment. That said, those things that provide relief for other people do not have the same effect on me. So, let's just say, I don't want to waste your time. Thanks.
0
0
Khaleedow Bright
8 months ago
Hello, I'm Khaleedow, an expert in fundraising. I came across your campaign and see that it is not getting enough investments because it is missing out on a crucial component which is Organic promotion.
I can help you promote your campaign organically and make it reach real and active investors who will be interested and willing to invest in your campaign.
You can reach me out or contact me through this link below
https//www.fiverr.com//khaleed011
0
0
John Dinusson
Eva Medtec
•
9 months ago
Wendy,
Neuroglide is sold primarily through physicians and therapists. The Neuroglide has been approved by The FDA as a Class II OTC (over the counter) device for pain and circulation. This classification allows the Neuroglide to be sold directly to patients as well. As mentioned below the company is exploring reimbursement from Medicare, private insurance, worker's compensation and the Veteran's Administration. The company has sold over $100,000 to date via word of mouth. If you have any further question please do not hesitate to call me at 952-217-6366.
Best regards,
John
0
0
Wendy Bauerschmidt
9 months ago
What is the suggested price of the Neuroglide?
0
0
John Dinusson
Eva Medtec
•
9 months ago
Sonny,
Neuroglide is sold primarily through physicians and therapists. The Neuroglide has been approved by The FDA as a Class II OTC (over the counter) device for pain and circulation. This classification allows the Neuroglide to be sold directly to patients as well. As mentioned below the company is exploring reimbursement from Medicare, private insurance, worker's compensation and the Veteran's Administration. The company has sold over $100,000to date via word of mouth. If you you have any further question please do not hesitate to call me at 952-217-6366.
Best regards,
John
0
0
Sonny Park
9 months ago
How much is the device? Where is it sold? TIA.
0
0
John Dinusson
Eva Medtec
•
9 months ago
Jerry, the Neuroglide is currently not reimbursee by Medicare. However, we are exploring coding and payment for Medicare, private insurance, workers comp and the VA.
Best regards,
John
0
0
Jerry Irwin
9 months ago
Will insurance reimburse for your device?
0
0
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
Melinda Starbird
7 months ago
0
0